Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 |Industry: Pharmaceuticals
|Expensive Performer
Durability score
45 /100
Valuation score
23.3 /100
Momentum score
47.2 /100
Market Capitalizati...
42,348.9 Cr.
AVG Broker Target
886.2
PE TTM Price to Ear...
18.4
Aurobindo Pharma Ltd.    
14 Feb 2019
722.80
2.08%
Way2Wealth
Aurobindo Pharma's revenue grew 22% on a YoY basis to `5270 crs. in Q3. Growth was led by all business segments and markets. US and growth markets reported growth of 27% and 36% respectively on a YoY basis. Consolidated EBITDA increased to `1,086 Cr vs. `1,025 Cr in Q3 last year, an increase of...
default
Aurobindo Pharma Ltd. is trading below it's 30 day SMA of 764.78
Aurobindo Pharma Ltd.    
11 Feb 2019
722.80
2.08%
default
Promoters pledge increased to 2.3% of holdings in Dec 2018 qtr.
Aurobindo Pharma Ltd.    
11 Feb 2019
722.80
2.08%
Prabhudas Lilladhar
The Q3FY19 sales, adj. EBITDA and PAT beat our estimates by 9%, 3% and Change in Estimates | Target | Reco 8% respectively. While the injectable business was in line with guidance, its flat value erosion of US generics QoQ and efficient execution of new business...
Aurobindo Pharma Ltd. has gained 26.58% in the last 1 Year
Aurobindo Pharma Ltd.    
11 Feb 2019
722.80
2.08%
Nirmal Bang Institutional
Aurobindo Pharma's (APL) 3QFY19 revenues at Rs52,697mn were up 11% QoQ and also 7.9%/8.6% above our/consensus estimate, respectively. The growth was led by a strong performance across geographies/businesses, but the surprise element was Europe and ARV business which grew QoQ 12% and 15%, respectively. Going forward, ARV performance may sustain, but Europe is expected to normalise at a euro150mn run rate as against euro 162m witnessed during 3QFY19. Despite a strong show on revenue front, net earnings stood at Rs7,122mn (up 16% QoQ) and were 4.2% below our estimate, but 6.4% above consensus estimate. Net earnings growth was subdued as cost-of-sales margin increased by 240bps (QoQ), R&D; costs...
Promoters pledge increased to 2.3% of holdings in Dec 2018 qtr.
Aurobindo Pharma Ltd.    
09 Feb 2019
722.80
2.08%
HDFC Securities
Maintain NEUTRAL with a revised TP of Rs 800 (15x Dec-20E EPS). It is encouraging to see the US base businesses of many Indian pharma companies recovering sharply in 3QFY19, largely led by exit of big players. However, our concerns over Aurobindo (ARBP) remain related to the Sandoz acquisition, which will be completed by 1HFY20. We strongly believe that this acquisition will expand ARBPs exposure to commodity products and the portfolio will be highly prone to future competition.
Aurobindo Pharma Ltd. has gained 26.58% in the last 1 Year
Aurobindo Pharma Ltd.    
08 Feb 2019
722.80
2.08%
Motilal Oswal
grew ~22% YoY to INR52.7b (v/s our est. of INR47.6b), largely led by the US (~46% of sales) and API segment (~17% of sales). The US sales were up ~22% YoY, while API segment sales were up ~20% YoY. Other geographies also 8 February 2019 reported healthy growth. Gross margin (GM) contracted 340bp YoY to 55% (-200bp QoQ), partly due to one-time provision for penalty on supply failure of some products in the US market, and change in product mix. EBITDA margin also contracted ~300bp YoY (-100bp QoQ) to 20.6%. R&D; spend was higher by ~120bp YoY to 4.8% (as % of sales), partially offset by lower other expense (down ~150bp YoY). Forex gain stood at INR51m v/s INR7.3m YoY. Adjusting for forex gain and acquisition related exceptional expense, PAT increased by ~5% YoY to INR6.9b (v/s our est.
Number of FIIs/FPIs holding stock rose by 38 to 637 in Dec 2018 qtr.
Aurobindo Pharma Ltd.    
08 Feb 2019
722.80
2.08%
ICICI Securities Limited
Aurobindo Pharmaceuticals' Q3FY19 numbers were higher than Idirect estimates due to higher-than-expected sales in all geographies except the US. Revenues grew 21.5% YoY to | 5269.7 crore (I-direct estimate: | 5022.3 crore) mainly due to 27.4% YoY growth in the US EBITDA margins contracted 344 bps YoY to 20.7% (I-direct estimate: 21.0%) mainly due to lower gross margins. EBITDA grew 6.2% to | 1089 crore against I-direct estimate of | 1055.5 crore Adjusted net profit grew 25.4% YoY to | 737.3 crore (I-direct estimate: | 669.1 crore). The delta vis--vis EBITDA was due to...
Aurobindo Pharma Ltd. is trading below it's 30 day SMA of 764.78
Aurobindo Pharma Ltd.    
08 Feb 2019
722.80
2.08%
buy
Angel Broking
For 3QFY2019, Aurobindo Pharma (APL), the company posted sales of `5,175cr v/s. `4,269cr in 3QFY2018, a yoy growth of 21.2%. On the operating front, the EBITDA margin came in at 19.2% v/s. 22.5% in 3QFY2018. YoY decline is on the back of sales of certain high margin products in 3QFY18. Sequentially EBDITA margins expanded by
Way2Wealth released a report for Aurobindo Pharma Ltd. on 14 Feb, 2019.
Aurobindo Pharma Ltd.    
19 Jan 2019
722.80
2.08%
buy
Angel Broking
Aurobindo Pharma's subsidiary Acrotech Biopharma has acquired portfolio Outlook & Valuations: On valuation front, the company paid almost 1.6xMarketCap/sales (on upfront payment), which we believe is very attractive. The addition whole US$140mn will be paid up if the sales for the two said above products reach US$800mn; which we believe is attractive. On the Operating
Aurobindo Pharma Ltd. is trading below it's 30 day SMA of 764.78
Aurobindo Pharma Ltd.    
17 Jan 2019
722.80
2.08%
Motilal Oswal
17 January 2019 injectable products, intellectual property and commercial infrastructure from Spectrum Pharma for a cash consideration of USD160m. The acquired products are already commercialized in the US (contributed USD116.2m in CY17 and likely to have contributed ~USD105m in CY18 for Spectrum Pharma). For ARBP, these products are expected to generate sales of ~USD100m for the first 12 months post completion of the deal. portfolio analysis indicates four products are under patent, which are expiring over FY20-34. This is largely due to increased R&D; (76% of sales) and selling expenses (84% of sales) for Spectrum. Post-acquisition of the commercial portfolio by ARBP, the R&D; spend would get eliminated. In addition, selling expenses would reduce considerably as ARBP will use its own marketing platform. Pro forma P&L; (Exhibit 1) indicates PAT of USD10m in FY20, which will only increase on the back of an improvement in sales and profitability.
Way2Wealth released a report for Aurobindo Pharma Ltd. on 14 Feb, 2019.